


12

14

At a Glance


Profile HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas. The company holds and manages an international portfolio of some twenty-five promising companies. Many of these companies have their lead products at an advanced stage of development or already available on

the market. The portfolio companies are closely tracked and actively guided in their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).




Allocation of assets

Mainly invested in private companies and companies originating from the private companies portfolio.




Currency allocation of net assets

Emphasis on US dollar investments.



Development phase of portfolio companies¹⁾

Mainly invested in revenue generating companies or in companies with products at an advanced stage of development.



Therapeutic area of the lead products of portfolio companies¹⁾

Broadly diversified areas of activity.


1) Total investments as at 31.12.2014: CHF 984,0 million.

Key Figures and Performance

		31.12.2014	31.3.2014	31.3.2013	31.3.2012	31.3.2011
Key Figures						
Net assets	CHF million	1,062.6	920.3	601.0	546.4	593.2
Investments in private companies and funds		278.9	218.8	233.4	276.3	370.8
Investments in public companies		705.1	630.5	278.9	196.7	83.4
Cash and cash equivalents		98.2	46.5	51.7	41.2	155.4
Net cash flow from investing activities	CHF million	152.1	42.8	33.2	-39.9	146.3
Net result for the period/for the year	CHF million	237.0	353.5	67.0	-22.2	-53.1
Basic earnings per share	CHF	29.60	40.98	7.52	-2.35	-5.39
Net asset value (NAV) per share	CHF	137.50	108.76	68.35	60.40	61.56
Share price	CHF	97.65	75.50	51.35	41.50	44.60
Discount		-29.0%	-30.6%	-24.9%	-31.3%	-27.6%
Distribution per share	CHF		3.00	1.50		
Distribution yield			4.0%	2.9%		
Shares issued	Registered shares (m)	8.0	8.9	9.2	9.8	10.2
Shares outstanding	Registered shares (m)	7.7	8.5	8.8	9.0	9.6

		2014/2015 (9 months)	2013/2014	2012/2013	2011/2012	2010/2011
Performance (including distributions)						
Net asset value (NAV)		29.2%	61.3%	13.2%	-1.9%	-6.6%
Registered share HBMN		33.3%	50.0%	23.7%	-7.0%	-9.9%

Net asset value (NAV) and share price of HBM Healthcare Investments Ltd versus MSCI World Health Care Index
in CHF, indexed (12.7.2001 = 100)



Dear Shareholders

In the third quarter of the 2014/2015 financial year, HBM Healthcare Investments once again achieved substantial value growth. As at 31 December 2014, net asset value (NAV) per share had risen by 13.3 percent to CHF 137.50, while the share price was up a little more, by 15.9 percent to CHF 97.65.

These latest figures take value growth for the first nine months of the current financial year to 29.2 percent for NAV, and 33.3 percent for the share price. Consolidated profit for the period stands at CHF 237.0 million. Factoring in the total of CHF 95 million in cumulated share buy-backs and cash dividend to shareholders, net assets increased from CHF 920 million to CHF 1.062 billion.

As at 31 December 2014, net assets per share, based on the NAV of CHF 137.50, were composed as follows: cash (net of liabilities) CHF 6.30, investments in public companies CHF 91.23, investments in private companies and funds CHF 36.09, and other assets CHF 3.88. The per share components of cash and public companies alone thus represented the share price of CHF 97.65 on the balance sheet date, while the market disregarded entirely the value and considerable potential of private companies and investment fund holdings.

IPOs lift net asset value

Three public offerings from the portfolio of private companies were major drivers behind the increase in net asset value during the quarter under review:

Paratek Pharmaceuticals completed its merger with exchange-listed Transcept Pharmaceuticals, and secured more than USD 90 million in funding to conduct phase III trials of the new broad-spectrum antibiotic omadacycline. The valuation of HBM Healthcare Investments' holding rocketed by 349 percent, resulting in a book profit of CHF 53.7 million.

The German company **Probiodrug**, which is currently testing a compound for the treatment of Alzheimer's disease in a phase IIa trial, went public on the Amsterdam Euronext exchange. This increased the valuation of our holding by CHF 6.3 million.

The IPO of Danish company **Forward Pharma**, in which HBM Healthcare Investments indirectly holds around three percent through the Nordic Biotech fund, multiplied the book value of the fund by more than eight, and contributed a total of CHF 31.2 million to the nine-month result.

**„Significant value
is not reflected
in the share price.“**

Other major factors in this result were the performances of Skyepharma (contribution to result CHF +53 million; share price +40 percent), PTC Therapeutics (CHF +50 million; +98 percent), Pacira Pharmaceuticals (CHF +40 million; +27 percent), Basilea Pharmaceutica (CHF –11 million; –9 percent) and Cathay Industrial Biotech (CHF –11 million; –50 percent).

This positive result was also supported by the appreciation of the US dollar, which has gained 12 percent against the Swiss franc from the beginning of the financial year on 1 April 2014 up to the balance sheet day end of December.

Shortly before the end of 2014, Novartis accepted the first patients for a phase III trial of its ESBA1008 compound to treat age-related macular degeneration. This triggered a milestone payment of USD 88 million to the former shareholders of the Swiss company ESBAtech, which was acquired by Alcon (now Novartis) in 2009. The payment will generate cash proceeds of around CHF 13 million for HBM Healthcare Investments in the first quarter of 2015 and thus led to an increase in the risk-adjusted value of the expected milestone payment from **ESBAtech** by CHF 8.1 million as at the end of December 2014.

During the quarter under review, HBM Healthcare Investments invested USD 8 million, as lead investor, in **Vascular Dynamics**, a privately held company based in Mountain View, California. The entire financing round of USD 18 million will enable Vascular Dynamics to continue with a clinical registration trial of MobiusHD™, an implant to treat patients with resistant hypertension (high blood pressure). More than 74 million patients suffer from hypertension in the USA alone. In around a quarter of cases, blood pressure cannot be regulated sufficiently with either medication or lifestyle changes.

Outlook

A number of events that will have a bearing on the value of HBM Healthcare Investments are expected during the first calendar quarter of 2015. At Basilea, the US FDA's approval decision for the antifungal compound isavuconazole is anticipated on 8 March. In addition, on 5 March the FDA is expected to decide on extending approval for Pacira Pharmaceuticals' analgesic Exparel™ for the additional indication nerve block. A positive outcome will significantly boost the drug's market potential. We also expect further IPOs from the portfolio of private companies if market conditions remain favourable.



Dr Andreas Wicki
CEO



Erwin Troxler
CFO

Consolidated Interim Financial Statements

Consolidated balance sheet

	Notes	31.12.2014	31.3.2014
Assets (CHF 000)			
Current assets			
Cash and cash equivalents		98,156	46,490
Receivables		453	192
Financial instruments	(3)	4,579	431
Total current assets		103,188	47,113
Non-current assets			
Investments	(4)	983,986	849,340
Other financial assets	(5)	24,907	29,236
Total non-current assets		1,008,893	878,576
Total assets		1,112,081	925,689
Liabilities (CHF 000)			
Short-term liabilities			
Provisions	(8)	46,762	3,807
Other short-term liabilities		2,687	1,546
Total short-term liabilities		49,449	5,353
Shareholders' equity			
Share capital	(6)	468,029	520,650
Treasury shares	(6)	-22,146	-27,934
Capital reserve		342,891	390,797
Accumulated income/loss		273,858	36,823
Total shareholders' equity		1,062,632	920,336
Total liabilities and shareholders' equity		1,112,081	925,689
Number of outstanding shares (in 000)		7,728	8,462
Net asset value (NAV) per share (CHF)		137.50	108.76

Consolidated Interim Financial Statements

Consolidated statement of comprehensive income for the period 1 April to 31 December

(CHF 000)	Notes	Quarter ended 31.12.2014	Quarter ended 31.12.2013	9-month period ended 31.12.2014	9-month period ended 31.12.2013
Gains on investments	(4)	160,971	90,309	336,583	274,976
Losses on investments	(4)	-20,705	-17,071	-50,479	-35,065
Dividend income		31	0	64	11,970
Result from currency hedging transactions		0	0	0	236
Result from market hedging transactions	(3)	-8,016	0	-8,016	0
Gains from other financial instruments	(3)	5,772	0	10,038	551
Losses from other financial instruments	(3)	0	-550	0	0
Gains on other financial assets		8,342	952	6,633	1,845
Losses on other financial assets		0	0	-3,057	-1,771
Result from investment activities		146,395	73,640	291,766	252,742
Management fee	(8)	-3,074	-2,714	-8,987	-7,286
Performance fee	(8)	-21,629	0	-42,955	0
Personnel expenses		-428	-553	-1,286	-1,474
Other operating expenses		-371	-315	-1,357	-1,062
Result before interest and taxes		120,893	70,058	237,181	242,920
Financial expenses		-33	0	-149	0
Financial income		2	7	3	24
Income taxes		0	0	0	0
Net result for the period		120,862	70,065	237,035	242,944
Comprehensive result		120,862	70,065	237,035	242,944
Number of outstanding shares, time-weighted (in 000)		7,797	8,581	8,008	8,662
Basic earnings per share (CHF)		15.50	8.16	29.60	28.05

As the Company does not have options or similar instruments outstanding, diluted earnings per share are identical to basic earnings per share.

Consolidated Interim Financial Statements

Consolidated statement of cash flows

for the period 1 April to 31 December

(CHF 000)	<i>9-month period ended 31.12.2014</i>	<i>9-month period ended 31.12.2013</i>
Management fee paid	-8,987	-7,286
Other expenses paid (personnel and other operating expenses)	-2,985	-2,257
Net cash flow from operating activities	-11,972	-9,543
Interest payments received	3	24
Dividend payments received	64	11,970
Purchase of investments	-244,825	-160,247
Sale of investments	395,454	192,055
Payments received from escrow amounts and milestones	3,569	8,584
Net cash flow from financial instruments to hedge market risks	-12,595	0
Net cash flow from other financial instruments	10,469	2,236
Net cash flow from investing activities	152,139	54,622
Interest payments paid	-149	0
Par value repayment	0	-12,948
Cash distribution from capital reserve	-23,588	0
Purchase of treasury shares	-77,738	-19,614
Sale of treasury shares	7,410	4,925
Sale of put-options from share buy-back programme	148	0
Net cash flow from financing activities	-93,917	-27,637
Currency translation differences	5,416	-1,912
Net change in cash and cash equivalents	51,666	15,530
Cash and cash equivalents at beginning of period	46,490	51,691
Cash and cash equivalents at end of period	98,156	67,221

Consolidated Interim Financial Statements

Consolidated statement of changes in equity

(CHF 000)	Share capital	Treasury shares	Capital reserve	Accumulated income/loss	Total shareholders' equity
Balance as at 31 March 2013	552,000	-19,867	385,527	-316,699	600,961
Comprehensive result				242,944	242,944
Purchase of treasury shares		-19,614			-19,614
Sale of treasury shares		4,170	755		4,925
Capital reduction (30.8.2013)	-18,000	14,718	3,282		0
Par value repayment (9.9.2013)	-13,350		402		-12,948
Balance as at 31 December 2013	520,650	-20,593	389,966	-73,755	816,268
Comprehensive result				110,578	110,578
Purchase of treasury shares		-9,522			-9,522
Sale of treasury shares		2,181	831		3,012
Balance as at 31 March 2014	520,650	-27,934	390,797	36,823	920,336
Comprehensive result				237,035	237,035
Purchase of treasury shares		-78,709			-78,709
Sale of treasury shares		5,511	2,047		7,558
Distribution from capital reserve (27.6.2014)			-23,588		-23,588
Capital reduction (26.8.2014)	-52,621	78,986	-26,365		0
Balance as at 31 December 2014	468,029	-22,146	342,891	273,858	1,062,632

Consolidated Interim Financial Statements

Notes

1. Information about the Company and its business

HBM Healthcare Investments Ltd ("Company") is a SIX Swiss Exchange listed holding company domiciled in Zug, Switzerland. The purpose of the Company is the acquisition, holding and sale of positions in other companies as well as the management and financing of such positions in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas.

2. Accounting policies

The consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) IAS 34 on Interim Financial Reporting, and the provisions of the SIX Swiss Exchange Additional Rules on the Listing of Investment Companies. These interim financial statements should be read in conjunction with the Consolidated Financial Statements for the financial year ended 31 March 2014, as they provide an update to the latest full financial report. In preparing the interim financial statements, the same accounting policies and methods of computation have been

4. Investments

Investments developed as follows during the reporting period:

Development of investments (CHF 000)

	Private companies	Funds	Public companies	Total investments
Fair value as at 31 March 2014	139,380	79,419	630,541	849,340
Reclassification owing to IPO (Probiodrug)	-6,030		6,030	0
Reclassification owing to IPO (Paratek Pharmaceuticals)	-4,810		4,810	0
Adjusted fair value as at 31 March 2014	128,540	79,419	641,381	849,340
Purchases	16,442	19,533	208,850	244,825
Sales	-477	-2,637	-393,169	-396,283
Realised gains	0	1,179	205,212	206,391
Realised losses	-12,844	-7	-7,782	-20,633
Changes in unrealised gains/losses	14,302	35,448	50,596	100,346
Fair value as at 31 December 2014	145,963	132,935	705,088	983,986

Further details on investments can be found on pages 11 and 12.

applied as in the preparation of the annual financial statements. A summary of the new and revised IFRS/IAS standards and interpretations effective in the year under review is provided on page 44 of the Consolidated Financial Statements of the 2013/2014 Annual Report. The use of these standards and interpretations had no significant impact on the financial condition or the earnings situation of the Company, or on its accounting policies. The following exchange rates were used in the preparation of the financial statements:

(CHF)	31.12.2014	31.3.2014
DKK	0.1615	0.1631
EUR	1.2029	1.2180
GBP	1.5488	1.4739
SEK	0.1274	0.1367
USD	0.9943	0.8846

3. Financial instruments

To hedge general market risks, put options for a nominal value of USD 223 million with a maturity in March 2015 have been bought. This corresponds to about a fifth of the total value of investments.

5. Other financial assets

Other financial assets consist primarily of contractual claims to purchase price payments from earlier trade sales that are contingent on the achievement of defined targets (milestone payments). These claims are recorded at fair value through profit and loss in the interim financial statements by applying a probability-weighted valuation approach based on the assessment of the likelihood of occurrence

of certain future events. These claims are discounted over time with a discount rate of 11 percent (previous year: discount rate of 11 percent). The valuation measures applied refer to commonly used industry statistics as well as own guidelines and estimates. The following summary shows the value carried in the balance sheet compared with the potential cash flows:

(CHF million)	Book value as at 31.12.2014	Range of possible cash flows, minimum	Range of possible cash flows, maximum	Expected period of payment
ESBATech	16.8	13.1	65.4	2015–2020
Mpex ¹⁾	2.1	2.1	38.5	2015–2029
mtm laboratories	9.4	0.9	27.6	2016
Other companies	2.5	0.1	39.4	2015–2020
Total	30.8	16.2	>170.9	

1) There is no ceiling on potential cash flows. The amount shown here is calculated on the basis of a sales estimate.

Of the total book value as at 31 December 2014, CHF 24.2 million is carried under other financial assets (claims from investments held by HBM Healthcare Investments directly). A further CHF 6.6 million is reported under investments, other private companies (claims from investments held indirectly via HBM BioCapital). If the companies concerned are successful, these contractual claims could result in future payments which are many times the reported book value.

ESBATech

The company was acquired in September 2009 by Alcon Inc., which became a division of Novartis. The purchase price comprised an upfront payment and further milestone payments that are tied to the achievement of clinical development targets. In addition to the upfront payment of CHF 20.3 million, HBM Healthcare Investments has to date received a small initial milestone payment of CHF 0.1 million. Further milestone payments are expected from 2015 onwards.

Mpex

The company was acquired in April 2011 by Aptalis, which is now a subsidiary of Actavis. Aptalis is paying the purchase price in cash, a guaranteed portion in tranches up to 2014, and the remainder as milestone payments contingent on market licensing and sales successes. HBM Healthcare Investments has received all guaranteed payments. Further payments of approximately USD 6 million will fall due upon the approval of the Aeroquin™ antibiotic in Europe and in the USA. HBM Healthcare Investments is also entitled to turnover-based payments on product sales up to 2029. These may correspond to several times the current book value.

mtm laboratories

The company was acquired in July 2011 by Roche. The purchase price comprised an upfront payment and further performance-based milestone payments. HBM Healthcare Investments has so far received the upfront payment of CHF 46.4 million. The performance-related milestone payment is expected in 2016.

6. Shareholders' equity

6.1 Share capital and capital reserve

As at the balance sheet date, the Company's share capital amounted to CHF 468 million (previous year: CHF 520.7 million), divided into 8,000,503 registered shares (previous year: 8,900,000 shares) at a par value of CHF 58.50 each (previous year: CHF 58.50). The Ordinary Shareholders' Meeting of 20 June 2014 decided to cancel 899,497 of the Company's own shares. This capital reduction was entered in the Commercial Register of the Canton Zug on 26 August 2014. In addition to this capital reduction, the Shareholders' Meeting approved a withholding tax-exempt distribution to shareholders of CHF 3.00 per registered share drawn from the reserves from capital brought in. The payment was made on 27 June 2014.

6.2 Treasury shares

The Ordinary Shareholders' Meeting of 20 June 2014 authorised the Board of Directors to repurchase up to a maximum of 800,000 of the Company's own shares via a second trading line. The share buy-back programme is intended for the purpose of cancellation as part of a capital reduction and will be completed no later than 19 June 2017 ("share buy-back programme 2014"). The programme started on 3 November 2014. Under this share buy-back programme a total of 125,000 of the Company's own shares have been repurchased to date.

The Company holds 125,000 of its own shares (previous year: 210,400 own shares) as at the balance sheet date of 31 December 2014. The 899,497 of its own shares, which have been repurchased by the Company under the share buy-back programme 2012 via the second trading line and under the share buy-back through the issue of put-options, have been cancelled. In the 9-month period of the current financial year, a total of 720,497 of the Company's own shares were acquired at an average price of CHF 97.90 per share (previous year: 247,400 own shares at an average price of CHF 60.85 per share).

	Own shares
Own shares (second trading line) as at 31.3.2014	304,000
Purchase of shares via second trading line	30,600
Purchase of shares via buy-back through the issue of put-options	564,897
Reduction of share capital by means of cancellation of own shares as at 26.8.2014	-899,497
Purchase of shares under the share buy-back programme 2014	125,000
Own shares (second trading line) as at 31.12.2014	125,000

In addition, as at the balance sheet date, the HBM Healthcare Investments (Cayman) Ltd subsidiary holds 147,239 treasury shares (previous year: 142,584 treasury shares), acquired via the regular trading line. During the 9-month period up to the end of December 2014, a total of 97,026 treasury shares were acquired via the regular trading line at an average price of CHF 84.25 per share (previous year: 80,427 shares at CHF 56.70), while 83,452 treasury shares were sold at an average price of CHF 88.80 (previous year: 82,205 shares at CHF 59.92). The gain of CHF 2.0 million (previous year: gain of CHF 0.8 million) from trading in treasury shares, which is reported in shareholders' equity, is based on the proceeds of shares sold, minus the pro-rata average acquisition price of all shares purchased via the regular trading line.

7. Off-balance-sheet commitments

Investment commitments

HBM Healthcare Investments has the following investment commitments as at 31 December 2014:

	31.12.2014	31.3.2014
(CHF 000)		
HBM BioCapital I	376	1,000
HBM BioCapital II	24,092	40,021
Private companies	13,408	7,450
Funds	8,007	11,357
Total investment commitments	45,883	59,828

8. Management fee and performance fee

The annual management fee to HBM Partners amounts to 0.75 percent of the Company's assets plus 0.75 percent of the Company's market capitalisation. In the 9-month period up to the end of December 2014, HBM Partners was paid CHF 9.0 million (previous year: CHF 7.3 million).

A performance fee provision of CHF 43.0 million (previous year: no performance fee) was made during the reporting period because net assets as at the balance sheet date of 31 December 2014 exceeded the highest net assets used as the calculation basis for the last performance fee

payment. The provision will be adjusted during the current financial year according to the change in the difference of these two net asset figures. The cut-off date for the payment of any performance fee is 31 March of a financial year.

9. Transactions with related parties

HBM Healthcare Investments holds an investment in the Hatteras Venture Partners III fund, where Board member Robert A. Ingram serves as General Partner. For details on the investment commitment, paid-in capital and valuation, please refer to the overview of funds on page 12.

Investments

	Domicile	Investment currency (IC)	Amount disbursed as at 31.3.2014 (IC m)	Changes in the reporting period (IC m)	Amount disbursed as at 31.12.2014 (IC m)	Fair value as at 31.12.2014 (IC m)	Ownership as % of portfolio company	Fair value as at 31.12.2014 (CHF 000)	Fair value as at 31.3.2014 (CHF 000)
Private companies									
Advanced Accelerator Applications (AAA)	France	EUR	20.0	5.0	25.0	25.0	7.9	30,073	24,360
Ellipse Technologies ¹⁾	USA	USD	8.6		8.6	18.1	26.3	18,034	8,185
Tensys Medical ²⁾	USA	USD	12.9	2.2	15.1	15.1	100.0	14,964	11,367
Cathay Industrial Biotech	China	USD	28.0		28.0	14.0	12.6	13,920	24,769
Interventional Spine	USA	USD	18.0		18.0	12.0	31.1	11,969	14,999
Nabriva Therapeutics ³⁾	Austria	EUR	13.7	0.8	14.4	9.1	13.5	10,945	9,636
Medimpulse Holding	Switzerland	USD	4.4		4.4	8.3	20.7	8,247	7,337
Westmed Holding	USA	USD	7.0		7.0	6.5	21.7	6,452	5,740
MiCardia ³⁾	USA	USD	4.6	0.8	5.4	5.9	20.1	5,847	3,252
Kolltan ³⁾	USA	USD	4.4	0.2	4.6	5.0	3.2	4,964	3,891
Vascular Dynamics	USA	USD	0.0	4.0	4.0	4.0	8.9	3,977	0
Delenix Therapeutics ³⁾	Switzerland	CHF	8.4	0.3	8.8	3.4	15.5	3,395	6,041
Other investments								13,176	8,963
Total private companies								145,963	128,540

1) HBM Healthcare Investments holds an additional approx. 6.4% stake in the company indirectly via the MedFocus Fund since August 2005.

2) A lender of Tensys Medical Inc. has a conversion right for 30% of the total outstanding shares of Tensys Medical Inc. following conversion.

3) As explained in note 4 to the annual financial statements, this investment was made partly or wholly through HBM BioCapital I whose pro rata fees are reimbursed in full to HBM Healthcare Investments so that fees are not levied twice.

Funds	Domicile	Investment currency (IC)	Total commitment (IC m)	Payments in the reporting period (IC m)	Repayments in the reporting period (IC m)	Cumulative payments as at 31.12.2014 (IC m)	Cumulative payments as at 31.12.2014 (IC m)	Fair value as at 31.12.2014 (IC m)	Fair value as at 31.12.2014 (CHF 000)	Fair value as at 31.3.2014 (CHF 000)
Nordic Biotech	Denmark	DKK	31.0			31.0	11.8	220.5	35,620	4,425
HBM BioCapital II ¹⁾	Jersey	EUR	42.0	12.8		22.0	0.0	19.6	23,528	8,559
MedFocus Fund II	USA	USD	16.0			16.0	0.0	19.3	19,233	12,232
BioMedInvest I	Switzerland	CHF	26.0			26.0	14.0	15.0	15,002	15,418
Galen Partners V	USA	USD	10.0	0.2		9.6	0.0	9.5	9,476	9,310
Hatteras Venture Partners III	USA	USD	10.0	0.6		9.1	2.0	9.2	9,142	7,704
BioMedInvest II	Switzerland	CHF	10.0	2.0	0.8	8.0	0.8	7.6	7,550	7,447
Water Street Healthcare Partners	USA	USD	15.0		1.9	14.8	16.2	5.3	5,222	6,339
Other funds									8,162	7,985
Total funds									132,935	79,419

Public companies	Domicile	Investment currency (IC)	Number of shares as at 31.3.2014	Changes in number of shares in the last 9 months	Changes in number of shares in the last 3 months	Number of shares as at 31.12.2014	Ownership as % of portfolio company	Fair value as at 31.12.2014 (CHF 000)	Fair value as at 31.3.2014 (CHF 000)
Skyepharma	UK	GBP	11,503,145	14,064,399	0	25,567,544	24,4	132,659	40,691
Basilea Pharmaceutica ^{P)}	Switzerland	CHF	1,232,479	-82,339	-1,000	1,150,140	11,3	105,985	124,357
Pacira Pharmaceuticals ^{P)}	USA	USD	1,667,307	-567,307	0	1,100,000	3,1	96,970	103,228
Paratek Pharmaceuticals ²⁾	USA	USD	633,582	1,134,678	1,107,038	1,768,260	12,3	67,778	4,810
PTC Therapeutics ^{P)}	USA	USD	2,441,495	-1,441,495	-1,005,000	1,000,000	3,0	51,475	56,456
Ophthotech ^{P)}	USA	USD	3,640,230	-2,540,230	-900,000	1,100,000	3,3	49,076	114,879
Esperion Therapeutics	USA	USD	0	510,000	510,000	510,000	2,5	20,507	0
Swedish Orphan Biovitrum ^{P)}	Sweden	SEK	2,253,000	-228,000	0	2,025,000	0,8	20,465	21,831
Receptos	USA	USD	32,500	127,500	90,000	160,000	0,5	19,490	1,206
Enanta Pharmaceuticals ^{P)}	USA	USD	500,000	-150,000	0	350,000	1,9	17,696	17,688
Probiobdrug ²⁾	Germany	EUR	464,056	283,303	252,534	747,359	11,1	17,216	6,030
Genmab	Denmark	DKK	231,500	47,500	-5,000	279,000	0,5	16,237	8,319
St. Jude Medical	USA	USD	0	150,000	30,000	150,000	0,1	9,699	0
Aegerion	USA	USD	300,000	112,006	0	412,006	1,5	8,578	12,255
Incyte	USA	USD	9,500	99,500	0	109,000	0,1	7,924	450
Lpath	USA	USD	1,341,555	1,439,281	0	2,780,836	14,4	7,797	5,637
Chimerix	USA	USD	5,000	145,000	140,000	150,000	0,4	6,005	101
Morphosys	Germany	EUR	84,000	-20,000	0	64,000	0,2	5,899	6,886
K2M Group Holdings	USA	USD	0	200,000	0	200,000	0,5	4,150	0
Collectis	France	EUR	0	250,000	0	250,000	0,9	3,678	0
Nephrogenex	USA	USD	250,000	0	0	250,000	2,8	3,318	1,794
Skyepharma bond ³⁾	UK	GBP						0	84,106
Other investments								32,486	30,657
Total public companies								705,088	641,381
Total investments								983,986	849,340

1) The fair value of EUR 19.6 million takes into account the funds' cumulative management fees of EUR 2.4 million. As described in note 4 to the annual financial statements, this amount was reimbursed in full to HBM Healthcare Investments so that fees are not levied twice.

2) Paratek Pharmaceuticals and Probiobdrug listed their shares on NASDAQ and Euronext Amsterdam in October 2014. The investments were previously reported under private companies.

3) The bond was redeemed by Skyepharma on 2 May 2014, at a price representing 114.85% of the face value.

P) The position originates from the private companies portfolio.

Significant shareholders

Based on the notifications received by the Company, the following shareholders report equity holdings in HBM Healthcare Investments Ltd of three percent or more as at 31 December 2014:

Shareholding	Shareholder	Latest notification
10–15%	Alpine Select Ltd, Zug	14.1.2014
5–10%	Astellas Pharma Inc., Tokyo	25.1.2014
3–5%	Red Rocks Capital LLC, Golden, USA	5.6.2014
	HBM Healthcare Investments Ltd, Zug (treasury shares)	8.12.2014

Information on shares

SIX Swiss Exchange Ticker	HBMN
Bloomberg	HBMN SW Equity
Swiss security number	1.262.725
German security number	984345
ISIN	CH 0012627250
CUSIP	H 3553X112
Telekurs	126,126272
Internet	www.hbmhealthcare.com

Credits

Editorial HBM Healthcare Investments Ltd

Concept and realisation Weber-Thedy Strategic Communication

Design KÜNG Art Direction

Layout and print Bader + Niederöst AG

Copyright © 2015 HBM Healthcare Investments Ltd

The Quarterly Report is published in English and German.

The German version is binding in all matters of interpretation.

Board of Directors

Hans Peter Hasler, Chairman³⁾

Prof. Dr Dr h.c. mult. Heinz Riesenhuber¹⁾,
Vice Chairman

Mario G. Giuliani³⁾

Dr Eduard E. Holdener

Robert A. Ingram²⁾³⁾

Dr Rudolf Lanz¹⁾²⁾

Dr Benedikt Suter, Secretary of the Board of Directors

¹⁾ Member of the Audit Committee

²⁾ Member of the Nominating Committee

³⁾ Member of the Compensation Committee

Management

Dr Andreas Wicki, Chief Executive Officer

Erwin Troxler, Chief Financial Officer

Fees

Management fees (paid quarterly):

0.75% of the Company's assets plus

0.75% of the Company's market capitalisation

Performance fee (paid annually):

15% on increase in value above the high water mark

High water mark: NAV of CHF 103.21

(per share for all outstanding shares)

